The limits of general anesthesia

In addition to managing the administration of sedative and analgesic agents, the medical management of the patient operated by the anesthetists includes the control of breathing, the maintenance of hemodynamic parameters (blood pressure and heart rate) and the preservation of all Vital functions. The constant increase of interventions in patients with multiple pathologies makes this task increasingly complex.

The adaptation of the quantities of medicines throughout the surgical interventions is made according to the information provided by the monitoring elements used. It can be seen that, despite more numerous and precise devices, the incidence of side effects due to anesthesia persists.

It has been shown that a better control of the "depth" of anesthesia can significantly reduce these phenomena, such as the occurrence of post-operative nausea and vomiting, or episodes of confusion encountered in patients which may be the cause of long-term alterations in cognitive functions.

These side effects, in addition to causing additional inconvenience to the patient as a result of the operation, are very costly to society by increasing hospital morbidity, length of stay in hospital, long after the operation. This additional cost is estimated at 80 billion dollars annually in the world.

EASYTIVA, THE REGULATION OF GENERAL ANESTHESIA 

Medsteer, founded in 2010, develops the medical device EasyTIVA (literally Total Anesthesia Intra Venous Facilitated). This device regulates in real time the amount of anesthetic injected into the body during the operation from the patient's brain activity. It is the brain of the patient that drives its own anesthesia!
The device such as an autopilot system is used in the operating room under the supervision of an anesthetist. It allows better control of the depth of anesthesia of the patient than anesthesia staff can do. It allows anesthesiologists to concentrate on tasks that preserve general homeostasis.

MEDSTEER, A SOCIETY BASED AT THE HOSPITAL FOCH IN SURESNES (HAUTS-DE-SEINE) AND NEW YORK

-more than 11,000 patients

-25 Clinical Trials
-50 operating theaters
-150 anesthetists
-18 international patents that protect technology

Financed project